(Oslo, 2end of April 2024) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarters in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces the Annual General Meeting for the company.
The Annual General Meeting will take place on the 24th of April 2024 at 10.00 and is held at Medistim’s offices at Økernveien 94 in Oslo. Attached are the agenda for the meeting, the voting form and the annual report for 2023. It is possible to give proxy with and without voting instructions. By using a proxy with voting instructions, the shareholders will vote on the specific issues without personal attendance. For further information on the use of proxy, see general information at the bottom of the notice and enclosed proxy forms.
Attached is also the annual report for 2023 for Medistim ASA in PDF format and in ESEF format. The report will also be available on the company web site: www.medistim.com.
About Medistim:
Medistim was established in 1984, and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment, and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Canada, China, Germany, UK, Spain, Denmark, Sweden and Norway, in addition to the about 60 distributors in Europe, Asia, Middle East, Africa, Canada and South America. For more information, visit the Medistim home page: www.Medistim.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act (Verdipapirhandelloven).
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com